In reply: We thank Inglis and colleagues1 for their interest in our review article2 and for highlighting the important issue of a possible signal for increased thyroid cancer risk with glucagon‐like peptide 1 (GLP‐1) receptor agonists raised in the study by Bezin and colleagues.3
- 1. Inglis JM, Kichenadasse G, Mangoni AA. Current and emerging medications for the management of obesity in adults [letter]. Med J Aust 2023; 219: 187‐188.
- 2. Walmsley R, Sumithran P. Current and emerging medications for the management of obesity in adults. Med J Aust 2023; 218: 276‐283. https://www.mja.com.au/journal/2023/218/6/current‐and‐emerging‐medications‐management‐obesity‐adults
- 3. Bezin J, Gouverneur A, Pénichon M, et al. GLP‐1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384‐390.
- 4. Thompson CA, Stürmer T. Putting GLP‐1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 2022; 46: 249‐251.
- 5. Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). J Natl Cancer Inst 2020; 112: 810‐817.
- 6. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon‐like peptide‐1 receptor agonists activate rodent thyroid C‐cells causing calcitonin release and C‐cell proliferation. Endocrinology 2010; 151: 1473‐1486.
- 7. Sattar N, Lee M, Kristensen S, et al. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‐analysis of randomised trials. Lancet Diab Endocrinol 2021; 9: 653‐662.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.